U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H15NO
Molecular Weight 165.2326
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PSEUDOEPHEDRINE

SMILES

C[C@@]([H])([C@]([H])(c1ccccc1)O)NC

InChI

InChIKey=KWGRBVOPPLSCSI-WCBMZHEXSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H15NO
Molecular Weight 165.2326
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796

Pseudoephedrine is a sympathomimetic drug. Pseudoephedrine acts as an adrenomimetic and inhibitor of monoamine transporters. Ephedra sinica, a species of ephedra (ma huang), contains ephedrine and pseudoephedrine. Ephedra has been found to stimulate the nervous system, increase airflow into the lungs and constrict blood vessels. In combination with caffeine, ephedra appears to cause weight loss. Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, and hay fever and other respiratory allergies.

Originator

Sources: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889).
Curator's Comment:: (+)-threo-isomer of ephedrine, q.v. Isoln from E. vulgaris: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889). Synthesis: E. Späth, R. Göhring, Monatsh. Chem. 41, 319 (1920). reference retrieved from http://www.drugfuture.com/chemdata/pseudoephedrine.html

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SUDAFED 24 HOUR

Approved Use

temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies; reduces swelling of nasal passages; relieves sinus pressure

Launch Date

7.2429122E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
292 ng/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4346 ng × h/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.3 h
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
Other AEs: Rhabdomyolysis, Creatine kinase increased...
Other AEs:
Rhabdomyolysis (1 patient)
Creatine kinase increased (1 patient)
Blood myoglobin increased (1 patient)
Sources:
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Other AEs: Tension, Dry mouth...
Other AEs:
Tension (10 patients)
Dry mouth (6 patients)
Tachycardia (9 patients)
Palpitations (10 patients)
Anxiety (13 patients)
Insomnia (12 patients)
Anorexia (7 patients)
Restlessness (10 patients)
Sources:
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Urinary retention...
AEs leading to
discontinuation/dose reduction:
Urinary retention (acute, 1 patient)
Sources:
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
720 mg 1 times / day multiple, oral
Highest studied dose
Dose: 720 mg, 1 times / day
Route: oral
Route: multiple
Dose: 720 mg, 1 times / day
Sources:
unhealthy, 38.8 years
n = 38
Health Status: unhealthy
Age Group: 38.8 years
Sex: M+F
Population Size: 38
Sources:
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
Other AEs: Hypertension...
Other AEs:
Hypertension (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Blood myoglobin increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
Creatine kinase increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
Rhabdomyolysis 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
Palpitations 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Restlessness 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Tension 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Insomnia 12 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Anxiety 13 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Dry mouth 6 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Anorexia 7 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Tachycardia 9 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Urinary retention acute, 1 patient
Disc. AE
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Ischemic colitis 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
Abdominal pain acute, 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
Ischemic colitis 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
Abdominal pain acute, 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
Hypertension 1 patient
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Cetirizine/pseudoephedrine.
2001
Ischaemic colitis on pseudoephedrine.
2001 Aug
Cost-effectiveness of urinary dipsticks to screen asymptomatic catheter-associated urinary infections in an intensive care unit.
2001 Dec
Stereocontrolled Mannich reaction with enolizable imines using (S,S)-(+)-pseudoephedrine as chiral auxiliary. Asymmetric synthesis of alpha,beta-disubstituted beta-aminoesters and beta-lactams.
2001 Dec 28
Epinephrine analogues.
2001 Nov
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis.
2001 Nov
Chloroephedrine: contaminant of methamphetamine synthesis with cardiovascular activity.
2001 Nov 1
Biotransformation of benzaldehyde into (R)-phenylacetylcarbinol by filamentous fungi or their extracts.
2001 Oct
Acute psychosis due to the interaction of legal compounds--ephedra alkaloids in 'vigueur fit' tablets, caffeine in 'red bull' and alcohol.
2001 Oct
Cathinone (Khat) and methcathinone (CAT) in urine specimens: a gas chromatographic-mass spectrometric detection procedure.
2001 Oct
Relationship between expansion of the CAG repeat in exon 1 of the androgen receptor gene and idiopathic male infertility.
2001 Oct
Small-cell carcinoma of the esophagus: report of three cases and review of the literature with emphasis on therapy.
2001 Sep
Community pharmacists' experience of over-the-counter medicine misuse in Scotland.
2001 Sep
Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations.
2001 Sep
Separation and determination of ephedrine alkaloids and tetramethylpyrazine in Ephedra sinica Stapf by gas chromatography-mass spectrometry.
2001 Sep
Toxicity of over-the-counter cough and cold medications.
2001 Sep
Rapid chiral on-chip separation with simplified amperometric detection.
2001 Sep 14
Analysis of enantiomers giving partially overlapped peaks by using different treatments of the chromatographic ultraviolet signals: quantification of pseudoephedrine enantiomers.
2001 Sep 28
Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE.
2002
Generalized dermatitis due to pseudoephedrine.
2002 Aug
Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections.
2002 Feb 15
Pseudoephedrine causing mania-like symptoms.
2002 Feb 22
Immediate hypersensitivity due to pseudoephedrine.
2002 Jan
Maternal medication use and risks of gastroschisis and small intestinal atresia.
2002 Jan 1
Cerebral vasoconstriction and stroke after use of serotonergic drugs.
2002 Jan 8
Pharmacological characterization of a noninvasive, chronic, experimental dog model of nasal congestion.
2002 Jan-Feb
Acoustic rhinometry in the dog: a novel large animal model for studies of nasal congestion.
2002 Jan-Feb
Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.
2002 Jul
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use.
2002 Jun
Oral medications.
2002 Mar
Pseudoephedrine as a chiral auxiliary for asymmetric Michael reactions: synthesis of 3-aryl-delta-lactones.
2002 May 30
A moderate dose of pseudoephedrine does not alter muscle contraction strength or anaerobic power.
2002 Nov
[Blood supply of the lips].
2002 Oct
Severe adverse drug reactions due to pseudoephedrine from over-the-counter medications.
2002 Sep
Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion.
2002 Sep-Oct
Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers.
2003
Baboon syndrome due to pseudoephedrine.
2003 Apr
[Improving the medical treatment of minors who are victims of sexual assault or physical abuse: a receiving center and partnership between a psychiatric hospital and university hospital].
2003 Apr
Sensitive determination of ephedrine and pseudoephedrine by capillary electrophoresis with laser-induced fluorescence detection.
2003 Apr
Nonpigmenting solitary fixed drug eruption caused by a Chinese traditional herbal medicine, ma huang (Ephedra Hebra), mainly containing pseudoephedrine and ephedrine.
2003 Apr
Physiological, subjective and performance effects of pseudoephedrine and phenylpropanolamine during endurance running exercise.
2003 Jan
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs.
2003 Jul
Development and validation of a capillary zone electrophoresis method for the determination of ephedrine and related compounds in urine without extraction.
2003 Jul 5
Chiral analysis of amphetamine-type stimulants using reversed-polarity capillary electrophoresis/positive ion electrospray ionization tandem mass spectrometry.
2003 Jun
[Tobacco: knowledge, reasoning and opinion of high school students in Doubs. Reflections on prevention].
2003 Mar
In vitro evaluation of apical microleakage following canal filling with a coated carrier system compared with lateral and thermomechanical Gutta-Percha condensation techniques.
2003 May
A comparative study of root canal preparation using FlexMaster and HERO 642 rotary Ni-Ti instruments.
2003 May
Canine model of nasal congestion and allergic rhinitis.
2003 May
Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule.
2003 May 1
Press-coating of immediate release powders onto coated controlled release tablets with adhesives.
2003 May 20
Patents

Sample Use Guides

SUDAFED® 24 HOUR TABLET, EXTENDED RELEASE; ORAL (PSEUDOEPHEDRINE HYDROCHLORIDE) 240MG adults and children 12 years and older: a tablet with water every 24 hours children under 12 years: do not use this product in children under 12 years of age
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: Pseudoephedrine inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:17:56 UTC 2021
Edited
by admin
on Sat Jun 26 09:17:56 UTC 2021
Record UNII
7CUC9DDI9F
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
PSEUDOEPHEDRINE
HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
(1S,2S)-(+)-PSEUDOEPHEDRINE
Common Name English
(.ALPHA.S)-.ALPHA.-((1R)-1-(METHYLAMINO)ETHYL)BENZENEMETHANOL
Systematic Name English
(+)-(1S,2S)-PSEUDOEPHEDRINE
Common Name English
PSEUDOEPHEDRINE [VANDF]
Common Name English
ACUNASO
Brand Name English
1-(S),2-(R)-ERYTHRO-(+)-EPHEDRINE
Common Name English
BENZENEMETHANOL, .ALPHA.-((1S)-1-(METHYLAMINO)ETHYL)-, (.ALPHA.S)-
Systematic Name English
PSEUDOEPHEDRINE [INN]
Common Name English
PSEUDOEPHEDRINE [HSDB]
Common Name English
(+)-THREO-EPHEDRINE
Common Name English
PSEUDOEPHEDRINE [WHO-DD]
Common Name English
PSEUDOEPHEDRINE [MI]
Common Name English
PSEUDOEPHEDRINE [MART.]
Common Name English
EPHEDRINE HYDROCHLORIDE IMPURITY B [EP]
Common Name English
ISOEPHEDRINE, D-
Common Name English
BENZENEMETHANOL, .ALPHA.-(1-(METHYLAMINO)ETHYL)-, (S-(R*,R*))-
Systematic Name English
(+)-PSEUDOEPHEDRINE
Common Name English
PSEUDOEPHEDRINE, (+)-
Common Name English
NEODURASINA
Brand Name English
Classification Tree Code System Code
WHO-VATC QR01BA02
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
CFR 21 CFR 119.1
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
WHO-VATC QR01BA52
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
NDF-RT N0000175552
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
NCI_THESAURUS C29709
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
CFR 21 CFR 1314.20
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
WHO-ATC R01BA02
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
LIVERTOX 813
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
NDF-RT N0000000209
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
WHO-ATC R01BA52
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
CFR 21 CFR 1315.13
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
Code System Code Type Description
CAS
90-82-4
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
IUPHAR
7286
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
EPA CompTox
90-82-4
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
EVMPD
SUB10157MIG
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
DRUG BANK
DB00852
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
RXCUI
8896
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY RxNorm
FDA UNII
7CUC9DDI9F
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
INN
1061
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
MESH
D054199
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
LACTMED
Pseudoephedrine
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
RXCUI
407885
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
ALTERNATIVE
NCI_THESAURUS
C61914
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
MERCK INDEX
M9294
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
202-018-6
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
ChEMBL
CHEMBL1590
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
WIKIPEDIA
PSEUDOEPHEDRINE
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
HSDB
3177
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
PUBCHEM
7028
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
DRUG CENTRAL
2326
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> AGONIST
SUB_CONCEPT->SUBSTANCE
DIASTEREOISOMER -> DIASTEREOISOMER
Related Record Type Details
METABOLITE -> PARENT
MAJOR
Related Record Type Details
PARENT -> IMPURITY
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC